Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Texas Instruments Incorporated (TXN) Price & Performance

Novo Nordisk A/STrade
Texas Instruments IncorporatedTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Texas Instruments Incorporated — how do they compare? Novo Nordisk A/S trades at $46.24 (market cap $207.85B), while Texas Instruments Incorporated trades at $279 (market cap $256.84B). The key difference: Texas Instruments Incorporated is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

NVOTXN
Market Cap
$207.85B$256.84B
Sector
HealthTechnology
52-Week High
$63.98$332.35
52-Week Low
$35.29$153.33
Enterprise Value
$222.55B$263.89B
Dividend Yield
3.81%2.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Texas Instruments Incorporated

Texas Instruments (TXN) trades at $280.44, down 1.97% on the day, with a bullish technical signal from moving averages. Recent earnings show beats in Q1 and Q2 2026, with Q3 expected at $2.37 EPS. The company maintains strong profitability with a 31.11% net margin and a 34.97% ROE, though valuation ratios like a P/E of 42.74 appear elevated. Positive sentiment is driven by AI data center demand and a smooth CFO transition announced in June 2026.

Outlook is cautiously optimistic with a consensus price target of $334.75, implying 19% upside, supported by AI growth and operational leverage. Risks include high debt-to-asset ratio of 40.61% and competitive pressures in semiconductors. Investors should weigh strong cash flow and dividend yield against valuation concerns for long-term holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Texas Instruments Incorporated

Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.

Read more on TXN